Mind Medicine (NEO: MMED) (OTCQB: MMEDF) (“MindMed”) recently announced that it was providing funding for a Phase 1 clinical trial aimed at evaluating the main psychotropic active ingredient dimethyltryptamine (“DMT”) found in ayahuasca. This clinical trial is slated to begin in the fourth quarter of this year.
DMT occurs naturally and is the primary reason why the indigenous shamanic practitioners in the Amazon use ayahuasca in their ceremonies. However, DMT quickly triggers its psychoactive effects and these effects also wear off a lot sooner than those of other psychedelic ingredients like LSD and psilocybin.
When DMT is administered as an ayahuasca brew, the other natural substances included in the brew prolong the effects of this psychotropic ingredient and also slow down the rate at which it is metabolized in the body.
Today, there is a growing trend of using DMT for therapeutic purposes. Unfortunately, there isn’t ample scientific data on DMT’s safety profile or clinical data indicating that DMT can be used as a medicine.
The planned Phase 1 clinical trial is intended to bridge these gaps by helping the research community to understand the best dosages of DMT and the medicinal effects which can be expected.
The Leichti Lab and Mind Medicine Inc. clinical trial will focus on delivering DMT intravenously. This will shine the light on the anecdotal reports about the possibility of using DMT to treat a variety of addiction disorders. The data collected from this trial will also be used by the researchers to design subsequent clinical trials aimed at developing medicine from DMT.
DMT is metabolized rapidly when it is taken orally, and this rapid action reduces the therapeutic window of the psychedelic substance. The Mind Medicine research team believes that if the ingredient is administered through a continuous perfusion, it is possible to lengthen the time during which DMT is active for up to 2 hours.
The Phase 1 clinical trial will therefore try to establish what starting dose as well as maintenance dose is appropriate to provide a stable psychedelic experience for patients undergoing DMT-assisted therapy sessions. The intravenous way of administering DMT allows trained professionals to induce or terminate the psychotropic trip of a patient at will.
At the moment, no study has shed light on the elimination half-life of ayahuasca or DMT. Similarly, there is no reliable data on the safe dosage of pure DMT. This Phase 1 clinical trial is set to go a long way towards providing this vital information, and proof of concept trials will then be conducted to take DMT a step closer to becoming a medicinal ingredient. How long it takes to get to that point remains to be seen.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.